David Mountcastle

CFO David Mountcastle sells 24.7K PRVA shares at $27.50 under 10b5-1 plan; retains 186.7K shares post-sale

David Mountcastle, EVP & Chief Financial Officer, sold 24,734 shares of Privia Health Group at $27.50 on 2026-07-02 under a pre-arranged 10b5-1 trading plan, reducing his holdings by 11.7% to 186,728 shares. The sale occurs with the stock at $27.23 currently, near its 52-week high of $27.70, and follows strong 30-day (+25.9%) and 90-day (+19.9%) price appreciation. Across his prior two trades at PRVA, similar sales on 2025-12-12 and 2025-02-14 were followed by negative 90-day returns of -13.2% and -1.0% respectively, establishing a historical pattern at this ticker. The transaction is structured and scheduled under a 10b5-1 plan rather than discretionary, so it reflects pre-committed execution timing rather than a contemporaneous market signal.

Privia CFO Mountcastle sells 23,887 shares ($597.9K) at $25.03; stock now -9.8% from 52-week high with elevated P/E of 158.73

David Mountcastle, EVP and Chief Financial Officer of Privia Health Group, sold 23,887 shares at $25.03 on December 12, 2025, reducing his holdings by 12.1% to 172,909 shares. At the current price of $23.81, the stock trades -9.8% from its 52-week high of $26.40, and Mountcastle's prior sell at this ticker on 2025-02-14 posted a -1.0% return over 90 days, establishing a 1-for-1 well-timed pattern at PRVA. The company trades at a notably elevated P/E of 158.73 on net income of $6.9M against quarterly revenue of $580.4M, with modest annual revenue growth of 4.7%, suggesting valuation stretched relative to earnings generation. The combination of a material reduction in the CFO's position at near-peak price, coupled with a historical precedent of his prior PRVA sales preceding downward movement, warrants scrutiny of the company's near-term trajectory and cash flow trajectory."

CFO David Mountcastle sold 100,000 shares of PRVA for $2.5M on 2025-02-14; reduced holdings 38.8%.

David Mountcastle, EVP & CFO, executed a substantial sale of 100,000 shares at $25.15, reducing his holdings from 257,727 shares to 157,727 shares—a -38.8% reduction in position size. The transaction occurred near the 52-week high of $25.50, with the stock up 14.7% over the prior 30 days and 21.0% over 90 days, reflecting recent strong momentum. At current valuation metrics including a P/E of 231.82, the combination of a large CFO liquidation during sustained upward price movement and at/near historical highs merits attention, particularly given that Privia's revenue growth of 22.2% annually and latest quarterly net income of $3.5M suggest the company's valuation is pricing in significant future performance. Investors should monitor whether additional insider activity or forward guidance changes accompany this material reduction in the CFO's stake.